Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 18/20 | 1.00 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.73 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.73 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.73 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.73 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047797 | 0.92 | PLA2G1B (0.94) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL8323100 | 0.91 | PLA2G1B (0.83) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7017169 | 0.89 | PLA2G1B (1.00) | PLA2G1B | |
| SCHEMBL7012324 | 0.87 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL8326101 | 0.85 | PLA2G1B (0.75) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7012857 | 0.85 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL5892140 | 0.84 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL29711234 | 0.84 | PLA2G1B (1.00) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7012847 | 0.82 | PLA2G1B (1.00) | PLA2G1B | |
| SCHEMBL7050026 | 0.81 | PLA2G1B (0.69) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149000-A1 | Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds | SHIONOGI & CO., LTD. | 2003-08-07 | — | — | US | claimed |
| EP-1157704-A1 | REMEDIES OR PREVENTIVES FOR ISCHEMIC REFLOW FAILURE | SHIONOGI & CO., LTD. (JP) | 2001-11-28 | — | — | EP | claimed |
| EP-1037630-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2000-09-27 | — | — | EP | claimed |
| WO-1999024026-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | claimed |
| US-7098237-B1 | Remedies for ischemia reperfusion injury | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030149000-A1 | Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds | SHIONOGI & CO., LTD. | 2003-08-07 | — | — | US | disclosed |
| EP-1157704-A1 | REMEDIES OR PREVENTIVES FOR ISCHEMIC REFLOW FAILURE | SHIONOGI & CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149000-A1 | Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds | BAX, CASP3, CASP5 | PLA2G1B 2849/4885PLA2G2A 3271/4885PLA2G2E 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.